Australia markets closed

Bio-Gene Technology Limited (BGT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0520+0.0020 (+4.00%)
At close: 12:59PM AEST

Bio-Gene Technology Limited

400 Collins Street
Level 6
Melbourne, VIC 3000
61 3 9068 1062

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A., MBAExecutive Director of Research & Development and Executive Director235.86kN/AN/A
Mr. Timothy Owen Grogan B.Sc., LLBMD, CEO & DirectorN/AN/AN/A
Mr. Edmond Tern B.A., CPACFO & Joint Company SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University to refine the process for oil extraction; and with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for testing of Flavocide in grain storage. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

Corporate governance

Bio-Gene Technology Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.